



# Standard Pharmaceutical Product Information (Rx Product Only)

Final Version:  Introduction Type:  New Item:  Date: 02/20/10

**SPECIAL HANDLING AND STORAGE REQUIREMENTS\***

a. Temperature - Indicate the USP temperature range for this product.  
 Temperature Range:  Controlled Room - between 20 and 25 C (68° - 77° F)  
 Other Temperature Range Requirement:

b. Contact for temperature excursion questions:  
 Name:  Is this product to be shipped to customers on ice?  No  
 Number:  Is this product to be shipped to customers on dry ice?  No  
 Group E-mail:

c. Special regulations for product in any states?  
 Special returns requirements for this product?  No  
 Yes

d. Store product (unit of sale) upright?  
 Protect product (unit of sale) from light?  Yes  
 No

e. Shelf life:  
 Initial shelf life at launch (if different):  Months  
 Months

**PRODUCT INFORMATION**

Company Name:  Application:  ANDA  
 Application Number for NDA/ANDA/BLA (drug):  A207057  
 DUNS:  Individual Unit NDC:  UPC:   
 Selling Unit NDC:  CVX Code:  MVX Code:   
 Description:

Active Ingredient(s):

URL for Additional Product Information:

Address:

City:  State:  Room:  205  
 Zip:  01080  
 Key Contact:  Email:  mbradley@lagpharma.com  
 Phone Number:  815-824-7685 Fax:  815-824-7687

Product Therapeutic Classification:

**ADDITIONAL PRODUCT INFORMATION**

Is the Product...  
 a legend device?  No  
 reverse numbered?  No  
 co-licensed?  No  
 Is the Product...  
 Direct Ship Only?  Neither  
 Is the Product...  
 Neither

If Unit Dose, is item bar coded to unit dose for hospital scanning?

If Unit Dose NDC, indicate NDC here:

Country of Origin:  China

Is this product covered under the Trade Agreements Act (TAA)?  No

**PRODUCT DESCRIPTION INFORMATION**

Size:  100 count  
 Strength:  600mg  
 Dosage Form:  Tablets

Product Shape:  oval  
 Product Color:  white  
 Product Imprint:

**FOR GENERIC DRUG PRODUCTS**

I. Orange Book Rating:  AB Authorized Generic  \*If Authorized Generic, other section fields are not applicable.  
 II. Generic Equivalent to What Brand?:

Does supplier meet DSCSA definition of manufacturer?  No  Yes  
 Is product exempt from DSCSA?  No  Yes  
 If yes, select exemption:  
 Other exemption - Write in:   
 Is product repackaged?  No  
 Is product sold by manufacturer's exclusive distributor?  No  
 Has FDA granted waiver/exemption for product?  No

**DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) INFORMATION**

Serialized?  Yes  
 If not, when?   
 Items aggregated?

Level:  Item  Box/Case  Pallet  
 Item:  X  X  X  
 Box/Case:  2D  2D  2D  
 Pallet:  2D  2D  2D

Quantity:

GTIN-14  
 00351224021501  
 30351224021502  
 50351224021506

**ITEM AND PACKING INFORMATION**

Item:	Weight Lbs.	Dimensions (US mmts.) Depth	Height	Width	Volume (Cubes)	# Pieces:
Box/Case/Bundle/Inner Pack:	0.3		4.55in	2.18in		1
Case:	3.6					12
Pallet:	33.06		16.53	14.17		108
UPC:	Case:					
	Carton:					

**PHARMACY ORDER / BILL UNIT**

Rec. sell unit to customer?

Each   
 Gram   
 Milliliter

**UNIT OF SALE**

X Bottle  
 Box/Case  
 Ampule  
 Glass  
 Tube  
 Vial Liquid Sgl  
 Vial Liquid Multi  
 Vial Powder Sgl  
 Vial Powder Multi  
 Other: Write in

**WHAT IS THE NDC SELLING UNIT?**  
 (Write-in, e.g. 1 Box of 10 Vials)

**MINIMUM ORDER QUANTITY?**

**IF YES, HOW MANY OF WHICH PACKAGE TYPE?**  
 Each   
 Inner/Case/Pack   
 Case

**COST INFORMATION**

Regular Cost   
 Invoice Cost (WAC) (\$)  \$15.60  
 Federal Excise Tax Per Unit of Sale   
 As of date:  7/5/2019

**WHOLESALE USE ONLY:**

Vendor #:   
 Whal. Code #:   
 Finesline Code:

Signature:  Melissa Bradley

\*Please provide any additional information on page 2.

Attach copy of SAFETY DATA SHEET (SDS) or non hazard letter, PACKAGE INSERT, LABEL AND PHOTO OF PRODUCT PACKAGING and BARCODE.  
 See new p. 3 for Designated Drop Ship Only.



# Standard Pharmaceutical Product Information (Page 2)

For Designated Drop Ship Only Products, Please Use Page 3

## MATERIAL HAZARD CLASSIFICATION and TRANSPORTATION

Is this product (check all that apply):

a. Cytotoxic?  No

b. CA Prop. 65 Carcinogen or Reproductive Toxicant?  
Is the product a CA Prop 65 carcinogen?  
Is the product a CA Prop 65 reproductive toxicant?  
Does the product label bear a CA Prop 65 warning?  
 No

c. Contact Hazard?  
d. Does this product require special clean-up instructions?  
(If yes, attach SDS with special instructions.)  
e. Does the product contain DEHP?  
 No

Is this product regulated for shipment by DOT or IATA?  
(If yes, answer a-e below and provide SDS)

a. UN/Identification Number

b. Proper Shipping Name

c. DOT Hazard Class

d. Packing Group

e. Inhalation Hazard?  No

SDS Hazard Classification

Organic  Corrosive

Inorganic  Oxidizer

Steroid/Androgen  Contact Hazard

Aerosol Class: Identify NFPA Storage Level:

Is the product a NIOSH hazardous drug?  
If yes, indicate which:

EPA Hazardous Waste Code:

Hazardous Waste Identification

REMS or REGISTRY RESTRICTIONS

Is there a REMS on this product?  
If Yes, is it managed with a pharmacy registry?  
Website URL:

Comments / Details: (For example, iPledge program?)

REMS:  No

REMS Program Manager Name:  Phone:

Supplier Manages REMS registry exclusively:  
Wholesale distributor support:

Provider Name:  DEA #:

Site Enrollment Number assigned by Supplier:  PCPDP #:

NPI #:

Comments

Registry:  Registry Program Contact Name:  Phone:

Comments

RETURN INSTRUCTIONS

Contact tel. # if product received damaged:

Is product returnable for credit:  Yes  No

URL/Link to returns policy:

Special regulations or returns requirements for this product in certain states?  
If so, which states? Other requirements? Comments?  
(Georgia, Mississippi and North Carolina. Requests can be made via fax: 815-624-7687 or email: customercare@tagpharma.com)

Comments:

Is the product restricted for air shipment? If so, indicate restriction:

Passenger

Cargo

Passenger & Cargo

Is this a reportable quantity?  No

RQ Threshold:

Is this a marine pollutant?  No

Is this product shipped utilizing an authorized DOT exception or Special Permit?  
(If yes, identify method below)

Limited Quantity

Consumer Commodity, ORM-D

Small Quantity (49 CFR 173.4)

Special Permit: DOT-SP

Special Provision (listed in Column 7 of 49 CFR 172.101);  
SP#

## ADDL STORAGE INFORMATION

Is the Product...  No

Controlled Substance?  No

Controlled by State(s)?  No

ARCOS Reportable?  No

Schedule No. (inc. N for non-narcotic)

Controlled Substance Code

Listed Chemical (List I or II)

If yes, indicate which:

Is it a scheduled listed chemical product?  No

## CLASS OF TRADE RESTRICTION:

No restriction: select YES if sold to retail pharmacy, hospitals, clinics and physician offices  Yes

Restricted to retail pharmacy only:  No

Restricted to hospital, clinics, and physician offices only:  No

Restricted from US territories? (explain in comments)  No

Comments:

MISCELLANEOUS NOTES and/or Image of Product Barcode:

Release DATE



# Standard Pharmaceutical Product Information (Page 3)

FOR DESIGNATED DROP SHIP PRODUCT ONLY - if not a designated drop ship, do not complete.

## Order Method for Designated Drop Ship Product

Purchase orders may be accepted by:

a. EDI	Yes	
b. Autofax	Yes	815-624-7687
c. Fax	Yes	815-624-7687
d. Phone only	No	855-225-8244
e. Supplier Web Site only	No	
Minimum Order Quantity:		855-225-8244
Supplier's Customer Service Number:		
Contracted 3PL company / contact #:	Name:	
	Phone:	

## Expedited Freight Charges or Other Designated Drop Ship Fees:

Expedited freight fees billed with each order: Yes  No

Drop Ship service fee billed with each order: Yes  No

Drop Ship miscellaneous fees billed: Yes  No

Comments:

## Class of Trade Restriction:

No restriction: Select YES if sold to retail pharmacy, hospitals, clinics and physician offices  Yes  No

Restricted to retail pharmacy only:  Yes  No

Restricted to hospital, clinics, and physician offices only:  Yes  No

Restricted from US territories? (explain in comments)  Yes  No

Comments:

## Other Data Information Required to Process PO:

Patient Procedure Date:

Physician Name:

Physician/Clinic Phone #:

Physician State License #:

Physician/Clinic DEA #:

Physician/Clinic Specialty:

## Miscellaneous Notes:

## Standard Order Receipt and Processing

Purchase order daily receipt cut off time by supplier:  Central

Cut off time:  Hours  Days

Shipping lead time of PO:

Ships same day for next day receipt:

Ships for second day receipt:

Ships regular ground for 3-10 days receipt:

## Overnight and Priority Overnight PO Processing

Overnight receipt available: Yes  No

PO Receipt cut off time:  Central

Days of week overnight is available:

Monday	<input checked="" type="checkbox"/>
Tuesday	<input checked="" type="checkbox"/>
Wednesday	<input checked="" type="checkbox"/>
Thursday	<input checked="" type="checkbox"/>
Friday	<input type="checkbox"/>

## Priority Overnight receipt available:

PO Receipt Cut off time:  Yes  No

## Saturday Overnight receipt available:

PO Receipt Cut off time:  Yes  No

Order receipt method: Phone:  Fax:

Other receipt method: Fax:  EDI:

Overnight Fees apply:  Yes  No

Other fees apply:

## Return Instructions

Contact # if product is received damaged:

Is product returnable for credit:

URL/Link to returns policy:

Special regulations or returns requirements for this product in certain states?

If so, which states? Other requirements? Comments?

Georgia, Mississippi and North Carolina. Requests can be made via fax: 815-624-7687 or email

## ADDITIONAL INFORMATION

Is product order for scheduled patient procedure?

Is product order for restocking purposes?

# SAFETY DATA SHEET

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/ UNDERTAKING

Material Name: Gabapentin Tablets 600mg/800mg

Trade Name: Gabapentin Tablets 600mg/800mg

Chemical Family: Mixture

Intended Use: Pharmaceutical product used for antiepileptic

Manufacturer Information

Company name CSPC Ouyi Pharmaceutical Co., Ltd.

Address No.276 Zhongshan West Road Shijiazhuang 050051,China

Telephone + 86-311-87896575

Website www.ouyipharma.com

Emergency phone number +1-877-436-7220

## 2. HAZARDS IDENTIFICATION

**Appearance:** White, elliptical, film-coated tablets

**Statement of Hazard:** Non-hazardous in accordance with international standards for workplace safety.

**Additional Hazard Information:**

**Short Term:** Dust may cause irritation (based on components) The active ingredient is not acutely toxic.

**Known Clinical Effects:** Adverse effects associated with therapeutic use include dizziness, tiredness, swelling, and nausea.

**EU Indication of danger:** Not classified

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Gabapentin	60142-96-3	262-076-3	Not Listed	73.0
Corn Starch	9005-25-8	232-679-6	Not Listed	*
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Poloxamer 407	9003-11-6	Not listed	Not Listed	*
Povidone	9003-39-8	Not listed	Not Listed	*

Purified water	7732-18-5	231-791-2	Not Listed	*
Candelilla wax	8006-44-8	232-347-0	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not listed	Not Listed	*

#### 4. FIRST AID MEASURES

**Eye Contact:** Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

**Skin Contact:** Remove contaminated clothing and shoes. Wash skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:** Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

**Inhalation:** Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

#### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** Not known

**Fire Fighting Procedures:** Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Use caution in approaching fire.

**Fire / Explosion Hazards:** Not applicable

#### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Additional Consideration for Spills:** Large Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

#### 7. HANDLING AND STORAGE

**General Handling:** If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Storage Conditions:** Store in a cool, dry place away from direct sunlight. Storage Temperature: Store as directed by product packaging.

#### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Refer to available public information for specific member state Occupational Exposure Limits.**

Refer to available public information for specific member state Occupational Exposure Limits.

**Gabapentin**

Pfizer OEL TWA-8 Hr: 1200µg/m<sup>3</sup>

**Corn Starch**

ACGIH Threshold Limit Value (TWA) 10 mg/m<sup>3</sup> TWA

Australia TWA 10 mg/m<sup>3</sup>

Belgium OEL - TWA Listed

Bulgaria OEL - TWA Listed

Czech Republic OEL - TWA Listed

Greece OEL - TWA Listed

Ireland OEL - TWAs Listed

OSHA - Final PELs - TWAs: 15 mg/m<sup>3</sup> total

5 mg/m<sup>3</sup>

Portugal OEL - TWA Listed

Spain OEL - TWA Listed

**Talc (non-asbestiform)**

ACGIH Threshold Limit Value (TWA) 2 mg/m<sup>3</sup> TWA

ACGIH OELs - Notice of Intended Changes Listed

Australia TWA 2.5 mg/m<sup>3</sup> containing no asbestos fibers

Austria OEL - MAKs Listed

Belgium OEL - TWA Listed

Bulgaria OEL - TWA Listed

Czech Republic OEL - TWA Listed

Denmark OEL - TWA Listed

Estonia OEL - TWA Listed

Finland OEL - TWA Listed

Greece OEL - TWA Listed

Hungary OEL - TWA Listed

Ireland OEL - TWAs Listed

Netherlands OEL - TWA Listed

OSHA - Final PELs - Table Z-3 Mineral D: TWA-20 mppcf

Poland OEL - TWA Listed

Portugal OEL - TWA Listed

Romania OEL - TWA Listed

Slovenia OEL - TWA Listed

Spain OEL - TWA Listed

Sweden OEL - TWAs Listed

**Magnesium stearate**

ACGIH Threshold Limit Value (TWA) 10 mg/m<sup>3</sup> TWA

Australia TWA 10 mg/m<sup>3</sup>

Belgium OEL - TWA Listed

Ireland OEL - TWAs Listed

Lithuania OEL - TWA Listed

Portugal OEL - TWA Listed  
Spain OEL - TWA Listed  
Sweden OEL - TWAs Listed

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Analytical Method:** Analytical method available for gabapentin. Contact Pfizer Inc for further information.  
**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.  
**Environmental Exposure Controls:** Refer to specific Member State legislation for requirements under Community environmental legislation.  
**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Not required for the normal use of this product. Wear protective gloves when working with large quantities.  
**Eyes:** Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.  
**Skin:** Not required for the normal use of this product. Wear protective clothing when working with large quantities.  
**Respiratory protection:** Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical State:** Film-coated tablets

**Color:** White Molecular

**Formula:** Mixture

**Molecular Weight:** Mixture

## 10. STABILITY AND REACTIVITY

**Chemical Stability:** Stable under normal conditions of use.

**Conditions to Avoid:** None known

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

## 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

### Gabapentin

Mouse Oral LD50 > 5000 mg/kg

Rat Oral LD50 > 5000 mg/kg

Rat IV LD50 > 2000 mg/kg

Mouse IV LD50 1000-2000 mg/kg

Rat Subcutaneous LD50 > 4000 mg/kg

### Povidone

Rat Oral LD50 100 g/kg

### Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

### Magnesium stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**

**Gabapentin**

Eye Irritation Rabbit Non-irritating

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

**Gabapentin**

52 Week(s) Rat Oral 250 mg/kg/day NOAEL Liver, Kidney

52 Week(s) Monkey Oral 250 mg/kg/day NOAEL None identified

13 Week(s) Mouse Oral 1000 mg/kg/day NOAEL No effects at maximum dose

**Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

**Gabapentin**

Reproductive & Fertility Rat Oral 500 mg/kg/day NOAEL Negative

Embryo / Fetal Development Mouse Oral 3000 mg/kg/day NOAEL No effects at maximum dose

Embryo / Fetal Development Rat Oral 300 mg/kg/day NOAEL Developmental toxicity, Not Teratogenic

Embryo / Fetal Development Rabbit Oral 1500 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity

Peri-/Postnatal Development Rat Oral 500 mg/kg/day NOAEL Negative

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Gabapentin**

Bacterial Mutagenicity (Ames) Salmonella , E. coli Negative

In Vitro Chromosome Aberration Hamster Lung Cells Negative

In Vivo Unscheduled DNA Synthesis Rat Hepatocyte Negative

In Vivo Chromosome Aberration Hamster Bone Marrow Negative

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

**Gabapentin**

2 Year(s) Mouse Oral, in feed 2000 mg/kg/day NOEL Not carcinogenic

2 Year(s) Male Rat Oral, in feed 1000 mg/kg/day NOEL Malignant tumors, Pancreas

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

**Povidone IARC:** Group 3

**Talc (non-asbestiform) IARC:** Group 3

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.



### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

EU Indication of danger: Not classified

#### **OSHA Label:**

Non-hazardous in accordance with international standards for workplace safety.

#### Canada - WHMIS: Classifications

##### **WHMIS hazard class:**

None required This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

<b>Gabapentin</b>	
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	262-076-3
<b>Corn Starch</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
<b>REACH - Annex IV - Exemptions from the obligations of Register:</b>	Present
EU EINECS/ELINCS List	232-679-6
<b>Poloxamer 407</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed

<b>Talc (non-asbestiform)</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	238-877-9
<b>Povidone</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
<b>Purified water</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2
<b>Candelilla wax</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	232-347-0
<b>Hydroxypropyl cellulose</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
<b>Magnesium stearate</b>	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	209-150-3

## 16. OTHER INFORMATION

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients.

**Issue Date:** 09/2017

**Prepared by:** CSPC Ouyi Pharmaceutical Co., Ltd.

**DISCLAIMER:** This information is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes.